الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Summary
The aim of the present study was to investigate the Lnc-RNA expression (Lnc-IRF2-3 and Lnc-ZNF667) in early stages of CLL patients and in healthy patients, find out the correlation between Lnc-ZNF667 and apoptotic genes (BAX, Bcl-2) in CLL patients. Also, correlate Lnc-IRF2-3 and Lnc-ZNF667 expression patterns with prognosis and prognostic markers to outline their possible role in CLL outcome. A total of 135 CLL patients were selected to participate in the study and 30 healthy patients as a control group which obtained from donor who don’t receive any chemotherapeutic regimen or radiation.
Lnc-IRF2-3 and Lnc-ZNF667 expression were significantly upregulated in CLL patients compared to healthy control while, BAX and Bcl-2 were significantly downregulated in CLL patients compared to healthy control
Plasma Lnc-IRF2-3 and Lnc-ZNF667 showed a statistically high significant correlation with other parameters (Rai-staging, Binet-staging, cytogenetics). However, there was no significant correlation with parameters (age and gender).
Plasma BAX and Bcl-2 showed a statistically high significant correlation with other parameters (Rai-staging, Binet-staging, cytogenetics is significant with Bcl-2 but non-significant with BAX). However, there was no significant correlation with parameters (age and gender).
In addition, we conduct ROC analysis to detect the potential application of Lnc-IRF2-3 and Lnc-ZNF667 in the prognosis of CLL. Our results showed that Lnc-IRF2-3 and Lnc-ZNF667 can be used as potential biomarkers for CLL.
ROC curve analysis of Lnc-IRF2-3 showed the best sensitivity and specificity than Lnc-ZNF667 in differentiation between CLL patients and healthy patients.